One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see gains as high as 113,000%!

Robert Davis Biography and Net Worth

CFO of Merck & Co., Inc.

Rob Davis is chief executive officer and president of Merck.

Previously, Rob served as Merck’s president, responsible for the company’s operating divisions — Human Health, Animal Health, Manufacturing and Merck Research Laboratories. Prior to that, he was executive vice president, Global Services, and the company’s chief financial officer.

Rob joined the company as chief financial officer in 2014 with additional responsibility for real estate operations, corporate strategy and business development. In 2016, his role was expanded to include responsibility for information technology and procurement, forming Global Services. He became president in April 2021 and CEO and a member of the board of directors on July 1, 2021.

Prior to joining Merck, Rob was corporate vice president and president of Baxter’s Medical Products business. During his tenure at Baxter, he held several other positions, including president of Baxter’s Renal business, chief financial officer and treasurer. Before joining Baxter in 2004, Rob held numerous positions of increasing responsibility over 14 years at Eli Lilly and Company.

Rob serves on the board of directors for Duke Energy Corporation and is chair of its finance and risk management committee and a member of the corporate governance committee. In addition, Rob is a board member of Project Hope, a non-profit organization focused on empowering health care workers to deliver expert care when and where it is needed most.

Rob received his J.D. from Northwestern University School of Law, his M.B.A. from Northwestern University’s Kellogg Graduate School of Management and his bachelor’s degree in finance from Miami University.

What is Robert M. Davis' net worth?: The estimated net worth of Robert M. Davis is at least $35.52 million as of April 28th, 2023. Mr. Davis owns 271,817 shares of Merck & Co., Inc. stock worth more than $35,523,764 as of April 25th. This net worth approximation does not reflect any other investments that Mr. Davis may own. Additionally, Mr. Davis receives an annual salary of $6,080,000.00 as CFO at Merck & Co., Inc.. Learn More about Robert M. Davis' net worth.
How old is Robert M. Davis?: Mr. Davis is currently 57 years old. There are 7 older executives and no younger executives at Merck & Co., Inc.. Learn More on Robert M. Davis' age.
What is Robert M. Davis' salary?: As the CFO of Merck & Co., Inc., Mr. Davis earns $6,080,000.00 per year. Learn More on Robert M. Davis' salary.
How do I contact Robert M. Davis?: The corporate mailing address for Mr. Davis and other Merck & Co., Inc. executives is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. Merck & Co., Inc. can also be reached via phone at (908) 740-4000 and via email at [email protected]. Learn More on Robert M. Davis' contact information.
Has Robert M. Davis been buying or selling shares of Merck & Co., Inc.?: Robert M. Davis has not been actively trading shares of Merck & Co., Inc. during the last quarter. Most recently, Robert M. Davis sold 143,329 shares of the business's stock in a transaction on Friday, April 28th. The shares were sold at an average price of $114.93, for a transaction totalling $16,472,801.97. Following the completion of the sale, the chief executive officer now directly owns 271,817 shares of the company's stock, valued at $31,239,927.81. Learn More on Robert M. Davis' trading history.
Who are Merck & Co., Inc.'s active insiders?: Merck & Co., Inc.'s insider roster includes Sanat Chattopadhyay (Insider), Frank Clyburn (EVP), Robert Davis (CFO), Richard Deluca (EVP), Kenneth Frazier (Insider), Julie Gerberding (EVP), Clark Golestani (EVP), Michael Holston (EVP), Rita Karachun (VP), Caroline Litchfield (CFO), Steven Mizell (EVP), Johannes Oosthuizen (Insider), Joseph Romanelli (Insider), Ashley Watson (SVP), and Wendell Weeks (Director). Learn More on Merck & Co., Inc.'s active insiders.
Are insiders buying or selling shares of Merck & Co., Inc.?: During the last year, Merck & Co., Inc. insiders bought shares 1 times. They purchased a total of 3 shares worth more than $341.04. During the last year, insiders at the sold shares 11 times. They sold a total of 460,551 shares worth more than $53,354,373.87. The most recent insider tranaction occured on February, 13th when insider Joseph Romanelli sold 1,000 shares worth more than $124,890.00. Insiders at Merck & Co., Inc. own 0.1% of the company. Learn More about insider trades at Merck & Co., Inc..
Information on this page was last updated on 2/13/2024.

Robert M. Davis Insider Trading History at Merck & Co., Inc.

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/28/2023	Sell	143,329	$114.93	$16,472,801.97	271,817
11/9/2022	Sell	167,613	$102.44	$17,170,275.72	247,593
10/5/2020	Sell	251,273	$81.03	$20,360,651.19	422,329
6/25/2019	Sell	216,718	$85.43	$18,514,218.74	354,378
3/25/2019	Sell	192,572	$82.38	$15,864,081.36	330,232

Robert M. Davis Buying and Selling Activity at Merck & Co., Inc.

Merck & Co., Inc. Company Overview

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Today's Range

Now: $130.71

$128.76

$132.80

50 Day Range

MA: $126.34

$120.54

$131.95

2 Week Range

Now: $130.71

$99.14

$133.10

Volume

12,747,423 shs

Average Volume

8,343,713 shs

Market Capitalization

$331.09 billion

P/E Ratio

933.64

Dividend Yield

2.43%

Beta

0.38

The World's First "$20 Trillion Drug?"

From Behind the Markets | Ad

Get the name of the stock here >>>

Robert Davis Biography and Net Worth

What is Robert M. Davis' net worth?

How old is Robert M. Davis?

What is Robert M. Davis' salary?

How do I contact Robert M. Davis?

Has Robert M. Davis been buying or selling shares of Merck & Co., Inc.?

Who are Merck & Co., Inc.'s active insiders?

Are insiders buying or selling shares of Merck & Co., Inc.?